Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vosoritide · Voxzogo 0.4Mg, BMN-111

Peptide · Agonist of natriuretic peptide receptor-B (NPR2) · developed by Biomarin Pharm

Approved FDA, Nov 2021
BMRN Developer
5 Registered trials

What is Vosoritide?

Vosoritide is a modified recombinant human C-type natriuretic peptide analog that binds natriuretic peptide receptor-B, counteracting FGFR3 downstream signaling through the MAPK pathway and promoting endochondral bone growth. It is studied in achondroplasia, idiopathic short stature and hypochondroplasia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Voxzogo 0.4Mg, BMN-111
Drug type
Peptide
Targets
natriuretic peptide receptor-B (NPR2), FGFR3 (binding partner it blocks)
Mechanism
Agonist of natriuretic peptide receptor-B (NPR2)
Pathways
MAPK/ERK signaling, chondrocyte proliferation and differentiation
Therapy area
Musculoskeletal
Developer
Biomarin Pharm (BMRN)
FDA status
Approved as Voxzogo 0.4Mg (November 19, 2021), NDA214938 · FDA label
UNII
7SE5582Q2P

✅ FDA-approved uses

From the indications section of the FDA label (version of Nov 25, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07441876 Phase 2/3 Achondroplasia Recruiting BMRN
NCT06455059 Phase 3 Hypochondroplasia Completed BMRN
NCT03424018 Phase 3 Achondroplasia Active not recruiting BMRN
NCT06382155 Phase 2 Idiopathic Short Stature Recruiting BMRN
NCT03989947 Phase 2 Achondroplasia Active not recruiting BMRN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AchondroplasiaHypochondroplasiaIdiopathic Short Stature

Other drugs acting on NPR2

More from Biomarin Pharm

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BMRN page.

Follow BMRN, the company behind Vosoritide

See BMRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMRN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.